Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 12, 2020 4:05 PM EDTReported Positive Data from Phase 1/2a Clinical Trial of OpRegen®; All Cohort 4 Patients Have Improved Visual Acuity at Twelve Months or as of Last Visit (Gained Between 8-25 Readable Letters) Entered into Agreements with Three Companies for Certain IP and Assets Provided Positive Clinical Update from SCiStar Trial of OPC1 for Spinal Cord Injury Strengthened Extensive IP Portfolio with the Issuance of 3 New U.S. Patents Awarded $3.2 Million in Grants from Israel Innovation Authority and NIH Extended Anticipated Cash Runway by Implementing Cost Savings Initiatives and... More
